Fight Flu, COVID, RSV: Your 2026-27 Vax Guide

As respiratory virus season approaches, the CDC's outlook for 2026-27 suggests hospitalization rates from influenza, COVID-19, and RSV will likely mirror those of the previous year. Public health specialists strongly recommend vaccination as the primary method for protection against these viruses.

Annual flu vaccination is advised for everyone aged 6 months and older, with specific vaccine formulations available for different age brackets and medical histories. High-dose and adjuvanted vaccines are recommended for those 65 and older, while recombinant options are available for individuals aged 9 and above. Some children may require two doses based on prior vaccination history.

Updated COVID-19 vaccines target the XFG strain, a recombinant Omicron variant. Recommendations vary by age and risk factors, with Moderna and Pfizer offering mRNA vaccines, and Novavax providing a protein-based option. Individuals can receive flu and COVID-19 vaccines during the same visit or spaced a week apart.

RSV vaccines are recommended for adults aged 75 and older, those aged 50-74 with increased risk, and pregnant individuals between 32-36 weeks gestation. For infants under 8 months whose mothers did not receive the vaccine, two monoclonal antibody shots are available. Certain young children at high risk may also be eligible.